Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)

Organon and Co587 enrolled

Overview

The purpose of this study is to evaluate the cholesterol lowering effectiveness and safety of two investigational drugs in patients with mixed hyperlipidemia (high cholesterol and high triglycerides).

The duration of treatment is 18 weeks.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Enrollment

587

Conditions

Hypercholesterolemia Hypertriglyceridemia

Interventions

MK0653, ezetimibeDRUG

Comparator: fenofibrate monotherapyDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * High cholesterol and high triglycerides Exclusion Criteria: * Patient has a condition which, in the opinion of the investigator, might pose a risk to the patient, interfere with participation in the study, or does not meet the additional criteria as required by the study

Outcomes

Primary Outcomes

Plasma LDL-C vs. fenofibrate for 12 weeks.

Secondary Outcomes

All plasma lipid parameters vs. ezetimibe; all non-LDL lipid parameters vs. fenofibrate; safety and tolerability.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.